1-甲基咪唑-5-甲酸乙酯 | 66787-70-0

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基咪唑-5-甲酸乙酯
• 中文别名: 1-甲基咪唑-5-羧酸乙酯
• 英文名称: ethyl 1-methyl-1H-imidazole-5-carboxylate
• 英文别名: ethyl 3-methylimidazole-4-carboxylate
• CAS: 66787-70-0
• 化学式: C₇H₁₀N₂O₂
• 分子量: 154.169
• InChiKey: AIPYAGWNEMVIJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  294.9±13.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 1-methylimidazole-5-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 1-methylimidazole-5-carboxylate
CAS number: 66787-70-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H10N2O2
Molecular weight: 154.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基咪唑-5-甲酸乙酯 在 吡啶 、 sodium carbonate 、 甘油 作用下， 生成 1-甲基-1氢-5-醛基-咪唑
  参考文献：
  名称：

  Studies on Imidazoles. III. 1-Substituted Analogs of Histidine and Histamine

  摘要：

  DOI：

  10.1021/ja01175a062
• 作为产物：
  描述：

  咪唑-4-甲酸乙酯 、 碘甲烷 以 甲醇 为溶剂， 反应 48.0h， 以71%的产率得到1-甲基咪唑-5-甲酸乙酯
  参考文献：
  名称：

  A new generation of aprotic yet Brønsted acidic imidazolium salts: low toxicity, high recyclability and greatly improved activity

  摘要：

  已开发出低抗菌毒性且非质子性、但在质子性添加剂存在下能作为布伦斯特酸催化剂的催化剂。这些催化剂可循环使用，活性显著提高（即使用量可减少10至50倍），并且适用范围比前一代更广。

  DOI：

  10.1039/c3gc40975a

文献信息

• [EN] NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DE 1,3-OXAZOLIDINE ET UTILISATION DE CES DERNIERS COMME INHIBITEURS DE LA RÉNINE
  申请人：NOVADEX PHARMACEUTICALS AB

  公开号：WO2011056126A1

  公开（公告）日：2011-05-12

  The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.

  本发明涉及某些新颖的1,3-噁唑烷化合物（I）的公式，以及制备这类化合物的方法，以及它们作为肾素抑制剂或肾素抑制剂的前药的用途。
• Synthesis and Structure-Activity Relationships of New (5R,8R,10R)-Ergoline Derivatives with Antihypertensive or Dopaminergic Activity.
  作者：Sachio OHNO、Yuko ADACHI、Masayuki KOUMORI、Kiyoshi MIZUKOSHI、Mitsuaki NAGASAKA、Kenji ICHIHARA、Ei-ichi KATO

  DOI：10.1248/cpb.42.1463

  日期：——

  containing nitrogen atoms to afford the new ergolines. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-methylergoline (4s, maleate: BAM-1110) exhibited potent dopaminergic activity, about 18-fold greater than that of bromocriptine mesylate. (5R,8R,10R)-8-(1,2,4-Triazol-1-ylmethyl)-6-propylergoline (8b, fumarate: BAM-1602) showed extremely potent dopaminergic activity, being about 220 and 1.15 times more active

  合成了一系列新的（5R，8R，10R）-麦角灵衍生物，并在有意识的自发性高血压大鼠和单侧6-羟基多巴胺诱导的黑质病变大鼠中测试了它们的降压和多巴胺能活性。由相应的麦角灵羧酸酯制备的（5R，8R，10R）-6-烷基-8-麦角灵甲醇被转化为甲苯磺酸酯，然后用各种含氮原子的五元杂环进行处理，得到新的麦角灵。（5R，8R，10R）-8-（1,2,4-三唑-1-基甲基）-6-甲基麦角灵（4s，马来酸酯：BAM-1110）表现出强力的多巴胺能活性，比溴隐亭高约18倍甲磺酸酯 （5R，8R，10R）-8-（1,2,4-三唑-1-基甲基）-6-丙基麦角灵（8b，富马酸酯：BAM-1602）显示出极强的多巴胺能活性，约为220和1。活性分别比溴隐亭甲磺酸盐和甲磺酸培高利特高15倍。几种化合物表现出有效的抗高血压活性。讨论了抗高血压和多巴胺能活动的构效关系。
• Derisking the Cu-Mediated ¹⁸F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands
  作者：Nicholas J. Taylor、Enrico Emer、Sean Preshlock、Michael Schedler、Matthew Tredwell、Stefan Verhoog、Joel Mercier、Christophe Genicot、Véronique Gouverneur

  DOI：10.1021/jacs.7b03131

  日期：2017.6.21

  Molecules labeled with fluorine-18 (18F) are used in positron emission tomography to visualize, characterize and measure biological processes in the body. Despite recent advances in the incorporation of 18F onto arenes, the development of general and efficient approaches to label radioligands necessary for drug discovery programs remains a significant task. This full account describes a derisking approach

  用氟 18 (18F) 标记的分子用于正电子发射断层扫描，以可视化、表征和测量体内的生物过程。尽管最近在将 18F 掺入芳烃方面取得了进展，但开发通用且有效的方法来标记药物发现计划所需的放射性配体仍然是一项重大任务。这个完整的描述描述了杂环正电子发射断层扫描 (PET) 放射性配体的放射合成方法，使用铜介导的 18F 氟化芳基硼试剂与 18F 氟化物作为模型反应。该方法基于一项研究，该研究检查了药物开发中常用的杂环的存在如何影响代表性芳基硼试剂的 18F-氟化效率，以及超过 50 种（杂）芳基硼酸酯的标记。这组数据允许将这种去风险策略应用于七种结构复杂的药物相关含杂环分子的成功放射合成。
• Muscarine antagonists
  申请人：Merck & Co., Inc.

  公开号：US05756508A1

  公开（公告）日：1998-05-26

  This invention is concerned with novel 1,3-dihydro-1-\x9b1-(1-heteroarylpiperidin-4-yl)piperidin-4-yl!-2H-benzimidaz olones, derivatives thereof, their preparation, method of use and pharmaceutical compositions. These compounds are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).

  这项发明涉及新型1,3-二氢-1-\x9b1-(1-杂环芳基哌啶-4-基)哌啶-4-基!-2H-苯并咪唑酮及其衍生物，它们的制备、使用方法和药物组合物。这些化合物具有抗胆碱作用，并可用于治疗和/或预防近视（通常称为近视）。
• NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS
  申请人：Sun Piaoyang

  公开号：US20130005730A1

  公开（公告）日：2013-01-03

  The present invention relates to certain novel 1,3-oxazolidine compounds of formula (I), to processes for making such compounds and to their utility as renin inhibitors or prodrugs of renin inhibitors.

  本发明涉及一些新型1,3-噁唑啉化合物(I)的公式，制备这些化合物的方法以及它们作为肾素抑制剂或肾素抑制剂的前药的用途。